| 1. |
- Bersani, Cinzia, et al.
(författare)
-
A model using concomitant markers for predicting outcome in human papillomavirus positive oropharyngeal cancer
- 2017
-
Ingår i: Oral Oncology. - : Elsevier. - 1368-8375 .- 1879-0593. ; 68, s. 53-59
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Head-neck cancer therapy has become intensified. With radiotherapy alone, 3-year disease-free survival (DFS) is 80% for HPV-positive TSCC/BOTSCC and better for patients with favorable characteristics, suggesting therapy could be tapered for some, decreasing side-effects. Therefore, we built a model to predict progression-free survival for patients with HPV-positive TSCC and BOTSCC. Material and methods: TSCC/BOTSCC patients treated curatively between 2000 and 2011, with HPV16 DNA/E7 mRNA positive tumors examined for CD8(+) TILs, HPV16 mRNA and HLA class I expression were included. Patients were split randomly 65/35 into training and validation sets, and LASSO regression was used to select a model in the training set, the performance of which was evaluated in the validation set. Results: 258 patients with HPV DNA/E7 mRNA positive tumors could be included, 168 and 90 patients in the respective sets. No treatment improved prognosis compared to radiotherapy alone. CD8(+) TIL counts and young age were the strongest predictors of survival, followed by T-stage <3 and presence of HPV16 E2 mRNA. The model had an area under curve (AUC) of 76%. A model where the presence of three of four of these markers defined good prognosis captured 56% of non-relapsing patients with a positive predictive value of 98% in the validation set. Furthermore, the model identified 35% of our cohort that was over-treated and could safely have received de-escalated therapy. Conclusion: CD8(+) TIL counts, age, T-stage and E2 expression could predict progression-free survival, identifying patients eligible for randomized trials with milder treatment, potentially reducing side effects without worsening prognosis.
|
|
| 2. |
- Bersani, Cinzia, et al.
(författare)
-
MicroRNA-155,-185 and-193b as biomarkers in human papillomavirus positive and negative tonsillar and base of tongue squamous cell carcinoma
- 2018
-
Ingår i: Oral Oncology. - : Elsevier. - 1368-8375 .- 1879-0593. ; 82, s. 8-16
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Three-year disease-free survival (DFS) is 80% for human papillomavirus (HPV) positive tonsillar and base of tongue cancer (TSCC/BOTSCC) treated with radiotherapy alone, and today's intensified therapy does not improve prognosis. More markers are therefore needed to more accurately identify patients with good prognosis or in need of alternative therapy. Here, microRNAs (miRs) 155, 185 and 193b were examined as potential prognostic markers in TSCC/BOTSCC.Material and methods: 168 TSCC/BOTSCC patients diagnosed 2000-2013, with known data on HPV-status, CD8(+) tumour infiltrating lymphocytes, tumour staging and survival were examined for expression of miR-155, -185 and -193b using Real-Time PCR. Associations between miR expression and patient and tumour characteristics were analysed using univariate testing and multivariate regression.Results: Tumours compared to normal tonsils showed decreased miR-155 and increased miR-193b expression. miR-155 expression was associated with HPV-positivity, low T-stage, high CD8(+) TIL counts and improved survival. miR-185 expression was associated with HPV-negativity and a tendency towards decreased survival, while miR-193b expression was associated with higher T-stage, male gender and lower CD8(+) TIL counts, but not with outcome. Upon Cox regression, miR-185 was the only miR significantly associated with survival. Combining miR-155 and miR-185 to predict outcome in HPV+ patients yielded an area under curve (AUC) of 71%.Conclusion: Increased miR-155 expression was found as a positive predictor of survival, with the effect mainly due to its association with high CD8(+) TIL numbers, while miR-185 independently associated with decreased survival. Addition of these miRs to previously validated prognostic biomarkers could improve patient stratification accuracy.
|
|
| 3. |
- Bersani, Cinzia, et al.
(författare)
-
Targeted sequencing of tonsillar and base of tongue cancer and human papillomavirus positive unknown primary of the head and neck reveals prognostic effects of mutated FGFR3
- 2017
-
Ingår i: Oncotarget. - : IMPACT JOURNALS LLC. - 1949-2553. ; 8:21, s. 35339-35350
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Human papillomavirus positive (HPV+) tonsillar cancer (TSCC), base of tongue cancer (BOTSCC) and unknown primary cancer of the head and neck (HNCUP) have better outcome than corresponding HPV- cancers. To find predictive markers for response to treatment, and correlations and differences in mutated oncogenes and suppressor genes between HPV+ TSCC/BOTSSCC and HPV+ HNCUP and HPV- TSCC/BOTSCC targeted next-generation sequencing was performed of frequently mutated regions in 50 cancer related genes.PATIENTS AND METHODS: DNA from 348 TSCC/BOTSCC and 20 HNCUP from patients diagnosed 2000-2011, was sequenced by the Ion Proton sequencing platform using the Ion AmpliSeq Cancer Hotspot Panel v2 to identify frequently mutated regions in 50 cancer related genes. Ion Torrent Variant Caller software was used to call variants.RESULTS: 279 HPV+ TSCC/BOTSCC, 46 HPV- TSCC/BOTSCC and 19 HPV+ HNCUP samples qualified for further analysis. Mutations/tumor were fewer in HPV+ TSCC/BOTSCC and HNCUP, compared to HPV- tumors (0.92 vs. 1.32 vs. 1.68). Differences in mutation frequency of TP53 and PIK3CA were found between HPV+ TSCC/BOTSCC and HNCUP and HPV- TSCC/BOTSCC. In HPV+ TSCC/BOTSCC presence of FGFR3 mutations correlated to worse prognosis. Other correlations to survival within the groups were not disclosed.CONCLUSIONS: In HPV+ TSCC/BOTSCC mutation of PIK3CA was most frequently observed, while TP53 mutations dominated in HPV- TSCC/BOTSCC. In HPV+ TSCC/ BOTSCC and HNCUP, mutations/tumor were similar in frequency and fewer compared to that in HPV- TSCC/BOTSCC. Notably, FGFR3 mutations in HPV+ TSCC/BOTSCC indicated worse prognosis.
|
|
| 4. |
- Nordfors, Cecilia, et al.
(författare)
-
Oral human papillomavirus prevalence in high school students of one municipality in Sweden
- 2013
-
Ingår i: Scandinavian Journal of Infectious Diseases. - : Informa UK Limited. - 0036-5548 .- 1651-1980. ; 45:11, s. 878-881
-
Tidskriftsartikel (refereegranskat)abstract
- The rise in human papillomavirus (HPV) infection has been suggested to be responsible for the increased incidence of oropharyngeal cancer in the Western world. This has boosted interest in oral HPV prevalence and whether HPV vaccines can prevent oral HPV infection. In a previous study we showed oral HPV prevalenceto be almost 10% in youth aged 15-23 y attending a youth clinic in Stockholm, Sweden. However, this may not be a generalizable sample within the Swedish population. Therefore, mouthwashes were used to investigate oral HPV prevalence in 335 Swedish high school students aged 17-21 y (median age 18 y), from 1municipality with 140,000 inhabitants. The presence of HPV DNA in the oral samples, as examined by a Luminex-based assay, was significantly lower in this cohort, only 1.8% (3.1% in females and 0.6% in males), as compared to our previous study.
|
|
| 5. |
- Sivars, Lars, et al.
(författare)
-
Human papillomavirus DNA detection in fine-needle aspirates as indicator of human papillomavirus-positive oropharyngeal squamous cell carcinoma : A prospective study
- 2017
-
Ingår i: Head and Neck. - : Wiley. - 1043-3074 .- 1097-0347. ; 39:3, s. 419-426
-
Tidskriftsartikel (refereegranskat)abstract
- Background. Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (SCC) has a better outcome than most head neck squamous cell carcinomas (HNSCCs) and an HPV-positive lymph node metastasis likely has an HPV-positive oropharyngeal SCC origin. Determining HPV-status in cervical lymph nodes by fine-needle aspiration cytology (FNAC) may be useful for diagnosis. Methods. FNACs from 66 patients with neck masses were prospectively examined for HPV DNA and HPV16 mRNA by a polymerase chain reaction (PCR)-based assay, and the data correlated to diagnosis and HPV-status obtained from histopathological specimens. Results. Aspirates from 17 of 66 patients, later diagnosed with HPV-positive oropharyngeal SCC, were HPV16 DNA-positive. HPV16 mRNA was detected in all cases with extractable RNA. All remaining FNACs, including 18 branchial cleft cysts, were HPV DNA-negative. HPV DNA status in the aspirates showed perfect concordance with corresponding biopsies. Conclusion. HPV16 DNA detection in fine-needle aspirations from neck masses is reliable and HPV16 DNA in a metastasis is a strong indicator of an HPV-positive oropharyngeal SCC.
|
|
| 6. |
- Tertipis, Nikolaos
(författare)
-
Hunting the end of the rainbow : prognostic biomarkers and human papillomavirus in tonsillar and base of tongue cancer
- 2015
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Aim: The aim of this thesis was to hunt for additional prognostic biomarkers in HPV positive TSCC and BOTSCC to identify patients that could if they wished, be enrolled in clinical trials for de-escalation of treatment. Background. Tonsillar squamous cell carcinoma (TSCC) and base of tongue squamous cell carcinoma (BOTSCC), which account for most oropharyngeal squamous cell carcinomas (OSCC) have been increasing in the last decades and now comprise almost half of all head and neck cancers (HNSCC) in Sweden. The main risk factors for HNSCC were originally considered to be smoking and alcohol however in 2007 the International Agency for Research on Cancer (IARC) acknowledged HPV infection as a risk factor for OSCC. It has been shown that patients with HPV positive OSCC and especially TSCC and BOTSCC have a much better clinical outcome (80% 3 year disease free survival, DFS) as compared to for patients with the corresponding HPV negative tumors (40%). Due the generally poor prognosis for HNSCC, treatment for HNSCC including TSCC and BOTSCC has been intensified, leading to more serious side effects for the patients. It has been proposed that due to the good prognosis of patients with HPV positive TSCC and BOTSCC such an aggressive treatment might be unnecessary and de-escalation of treatment would be of benefit. However, since 20% of patients with HPV positive tumors do not do well, additional prognostic biomarkers are needed for selecting patients that would be the best responders to less intensive treatment. Results: In paper I, high numbers of CD8+ tumor infiltrating lymphocytes (TILs) were shown to correlate with a favorable clinical outcome in both HPV DNA+ and HPV DNA- TSCC and BOTSCC. In addition, HPV DNA+ tumors were significantly more infiltrated than the HPV DNA- ones. In paper II, absence of HLA class I in HPV DNA+ OSCC was shown to be associated with increased survival of the patients while the opposite was true for normal expression. In paper III, the HLA-A*02 allele, common in the Scandinavian population, was demonstrated to be a negative prognostic factor for patients with HPV DNA+ TSCC and BOTSCC. Following that study, in papers IV and V, the expression of components of the antigen processing machinery (APM) were examined for nuclear and cytoplasmic staining and the absence of LMP10 nuclear staining as well as low LMP7 expression were disclosed to be correlated with increased survival of patients with HPV DNA+ TSCC and BOTSCC. Finally, in paper VI, biomarkers CD8+ TILs, HLA class I, HLA-A*02 and LMP10 were combined with clinical characteristics of age, stage of the patients with HPV DNA+ TSCC and BOTSCC in order to develop an algorithm allowing for prediction of the outcome of the patients and CD8+ TILs, age and stage of the patients were found to be most significant prognostic contributors. Conclusion: Investigating and combining our best prognostic biomarkers, we have developed an algorithm which makes use of different biomarker and clinical characteristics allowing for prediction of patients with good clinical outcome that will enable de-escalation of treatment
|
|
